Page 1,919«..1020..1,9181,9191,9201,921..1,9301,940..»

stem cell – FierceBiotech – Biotech Industry, Biotech News …

Posted: December 2, 2014 at 12:55 pm

Scientists from three Boston institutions have createdCellNet, a computer algorithm to assist scientists in their efforts to engineer specialized cells.

Johnson & Johnson has deepened its ties to regenerative medicine outfit ViaCyte, handing the biotech $20 million in exchange for a future stake in the company and the right to acquire its in-development diabetes medication.

Novartis is forging ahead with a prospective stem cell biotech buyout, agreeing to pay $35 million to grab a sizable equity stake in Gamida Cell while executing a short term option deal that will allow the pharma giant the right to gobble up the company for another $600 million split up between a $165 million upfront payout with the rest up for grabs in development and sales milestones.

Gene therapy 2.0 at bluebird bio is demonstrating some early signs of success with an upgrade to its experimental therapy for the genetic blood disorder beta-thalassemia demonstrating promising results in a pair of patients, weaning them off the regular blood transfusions needed to stay alive.

Miltenyi Biotec said today that the FDA had approved its device for humanitarian use in patients with acute myeloid leukemia (AML) who are getting allogeneic stem cell transplants from matched, related donors. The device, called the CliniMACS CD34 Reagent System, is designed to lower the risk of graft-versus-host disease (GVHD), which is a common complication of this type of transplant.

Israel's Pluristem Therapeutics is back in the spotlight with some positive results for its stem cell therapy in treating patients with a muscle injury, giving the biotech some good news in its up-and-down development path.

Celgene helped seal its reputation as one of the boldest dealmakers in biotech today, putting up $177.25 million in an upfront fee and equity stake while committing to more than $3 billion in milestones to partner on a slate of cancer stem cell programs in development at OncoMed.

This year's examination of our top 5 stories of the year says a lot about what works when you're creating a presence on the world wide web and how it can also deliver super-sized audiences on some odd bits of work.

Thursday night the biotech company offloaded the product, and its mesenchymal stem cell platform in regenerative medicine, to Australia's Mesoblast for $50 million in near-term cash and stock and up to $50 million more in milestones.

After more than a year of not-so-secret negotiations, Geron has finally auctioned off its long-stalled embryonic stem cell pipeline, handing it over to a newly created BioTime subsidiary in exchange for shares.

Read the original here:
stem cell - FierceBiotech - Biotech Industry, Biotech News ...

Posted in Iowa Stem Cells | Comments Off on stem cell – FierceBiotech – Biotech Industry, Biotech News …

COPD Stem Cell Treatment | Analytical Stem Cell

Posted: December 2, 2014 at 12:54 pm

Analytical Stem Cell is hosting treatment for COPD using stem cell therapy.

About Stem Cell Therapy for COPD

Autologous Adipose-derived Stem Cells (ASCs) are a novel therapy for patients with COPD. More than 12 million people are diagnosed with COPD in the United States every year and someone dies of COPD every four minutes. COPD is the fourth leading cause of death and in 2007 carried an economic cost of $42.6 billion in direct health care costs and lost productivity.

The two main subtypes of COPD are chronic bronchitis and emphysema and current thinking is that chronic inflammation plays a significant role in both types of COPD. Increasing evidence suggests that COPD has an autoimmune component1 and even after patients with COPD have quit smoking blood markers of active inflammation are still present. 2

Chronic bronchitis may be thought of as an inflammatory disease of the large airways. In this disease chronic exposure to inhaled irritants, most notably cigarette smoke, increases inflammation of the bronchi resulting in hyperplasia and hypertrophy of the mucus and goblet cells lining the bronchi. This causes obstruction of air flow to the lungs as well as the chronic productive cough characteristic of chronic bronchitis.3

Inflammation is also the cause of much of the resulting pathology in emphysema. Cigarette smoking and, to a lesser extent, inhalation of other irritants such as mining dust and air pollution, lead to oxidative stress with release of larger amounts of free radicals. The body responds by increasing the production of locally active inflammatory cytokines. In susceptible individuals the end result of the chronic inflammation is a destruction of alveolar walls. Collapse of the alveolar walls, in turn, results in decreased surface area for transfer of oxygen and exchange for carbon dioxide into the bloodstream. Collapse of air sacs also destroys the supporting infrastructure of the lungs, leading to a degree of lung collapse, particularly during expiration. Incomplete expulsion of air within the lungs occurs during exhalation by the time that air hunger leads to the need for another breath and emphysema patients need to breathe faster and work harder to maintain adequate oxygenation.

The Procedure

How and where is my therapy done?

All treatments are performed under medical supervision of the finest medical specialistsincluding plastic surgeons, neurosurgeons, neurologists, cardiologists, anesthetists, pediatricians, orthopedic surgeons and radiologists. Theclinics have the highest possible medical standard and patients are taken care off by a professional team of physicians, nurses, patient advisors, and other assistants.In the US, as well as abroad, all Physicians are licensed and have been specially trained in stem cell treatments.

Originally posted here:
COPD Stem Cell Treatment | Analytical Stem Cell

Posted in Idaho Stem Cells | Comments Off on COPD Stem Cell Treatment | Analytical Stem Cell

Stem Cells to Revolutionise the Future of Diagnostic and Therapeutic Medicine

Posted: December 2, 2014 at 12:47 pm

- As improved R&D climate supports development, stem cell therapeutics market expected to boom globally

KUALA LUMPUR, Malaysia, Dec. 2, 2014 /PRNewswire/ -- Stem cells have the potential to transform healthcare by enabling the cost-effective treatment of many conditions that currently have poor treatment options. This will be particularly important for the rapidly growing aged population as well as the rising proportion of patients with neurological and chronic conditions. Stem cells may enable regenerative treatments that avoid traditional drugs, devices and surgery for these patient groups.

New analysis from Frost & Sullivan, Analysis of the Global Stem Cell Market, finds that the market earned revenues of US$40.01 billion in 2013 and estimates this to nearly triple to US$117.66 billion in 2018 at a compound annual growth rate of 24.1 percent. The study covers human adult and embryonic stem cells. While North America is the market leader with more than half of the global stem cell market share, the Asia-Pacific is expected to record the highest compound annual growth rate (CAGR) during the forecast period. In fact, the APAC stem cell market, which was valued at US$5.60 billion in 2013, is projected to increase to US$18.71 billion by 2018.

For complimentary access to more information on this research, please visit: http://corpcom.frost.com/forms/APAC_PR_DJeremiah_P805-52_10Nov14.

"The overall R&D funding for stem cell research has increased significantly in the past 5 to 10 years and will reach desired heights in the years to come," said Frost & Sullivan Healthcare Consultant Sanjeev Kumar. "The number of venture capital firms investing in stem cell research has risen and government funding agencies have begun to acknowledge the future benefits of the stem cell industry."

While the stiff regulations that previously guarded stem cell research have begun to relax, other legal and ethical issues continue to hamper research. For instance, research institutes that adopt policies addressing concerns surrounding the use of human embryonic tissues may hinder the overall research process, which usually involves several collaborative enterprises. Other market challenges include insurers' reluctance to pay for expensive stem cell therapies and the likelihood that patients themselves will be unable to afford these treatments.

"The global stem cell industry is in an early stage of development, with a handful of small and large participants," noted Kumar. "In the near future, mergers, acquisitions and collaborations will accelerate growth, with multinational companies and larger pharmaceutical companies playing a key role in facilitating these activities. As the market evolves, standards and new regulatory frameworks are expected to ease market challenges."

In the meantime, the market's growth potential is being underlined by promising results from clinical trials and the escalating importance of stem cell banking services across the globe. Eventually, the technology is expected to play a crucial function in various areas including neurological disorders, orthopaedics, cancer, haematological disorders, injuries and wound care, cardiovascular diseases, spinal cord injuries, diabetes, incontinence and liver disorders. Therapeutics manufacturers are also likely to explore the relevance of stem cells in other areas and combine them with existing applications to enhance treatment options.

Analysis of the Global Stem Cell Market is part of the Life Sciences (http://www.lifesciences.frost.com) Growth Partnership Service program. Frost & Sullivan's related studies include: Analysis of the Global Infectious Disease Diagnostics Market, Western European Companion Diagnostics Market, Analysis of the Global Biosimilars Market, and Analysis of the US Retinal Therapeutics Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

See the article here:
Stem Cells to Revolutionise the Future of Diagnostic and Therapeutic Medicine

Posted in Cell Medicine | Comments Off on Stem Cells to Revolutionise the Future of Diagnostic and Therapeutic Medicine

Global Stem Cells Group and Portal Medestetica to Launch Latin American Stem Cell Portal

Posted: December 2, 2014 at 12:47 pm

MIAMI (PRWEB) December 01, 2014

GlobalStemCellsGroup.com has announced plans to team with Portal Medestetica, the largest physician portal in Lain America, to launch Portalstemcells.com, a new portal dedicated to providing physicians in Spain and Latin America with relevant information, clinical research news and products relating to stem cells and regenerative medicine.

The new collaboration between Global Stem Cells Group and Portal Medestetica will answer a growing need to expand the reach of high-impact news, studies and breakthroughs, and significantly advance the clinical utilization of stem cell research and clinical trials throughout Latin America. The Portalstemcells.com site is designed to help promote the latest state-of-the-art developments in regenerative medicine as they become available, and to share educational content with physicians throughout the region.

Portalstemcells.com will be the ideal vehicle to promote education and cutting-edge science throughout the region, says Ricardo de Cubas, founder of Global Stem Cells Group. The potential of regenerative medicine and stem cells therapies inspiring the medical community to find real opportunities to repair or replace tissue damaged from disease, relieve pain and provide the potential for curing chronic diseases where no cure existed before.

The Portalstemcells.com site is aimed at fostering growth and ethical development in the fast-moving field of stem cell medicine by filling a gap in the resources available throughout Latin America. The goal is to elevate the delivery of stem cell science in order to impact the lives of many patients worldwide.

For more information visit the Global Stem Cells website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Continue reading here:
Global Stem Cells Group and Portal Medestetica to Launch Latin American Stem Cell Portal

Posted in Cell Medicine | Comments Off on Global Stem Cells Group and Portal Medestetica to Launch Latin American Stem Cell Portal

Global Stem Cell Groups Stem Cell Training to Launch Post-graduate Studies Program in Stem Cell Therapies and …

Posted: December 2, 2014 at 12:46 pm

MIAMI (PRWEB) December 01, 2014

MIAMI, Dec. 1, 2014Stem Cell Training, Inc., a division of Global Stem Cells Group, Inc., has announced plans to launch a post graduate studies program in stem cell therapies and regenerative medicine in 2015.

The program will include five days of intensive, interactive training coursework with classroom instruction and laboratory practice through didactic lectures, hands-on practical experience in laboratory protocols and relevant lessons in regulatory practices. Global Stem Cells Group Advisory Board member Dr. David B. Harrell, PhD will teach the coursework and perform laboratory instruction, accompanied by a series of guest lecturers from the Global Stem Cells Group faculty of scientists.

Attendees will receive hands-on training in techniques for a variety of laboratory processes, and gain insight into the inner workings of a cGMP laboratory and FDA registered tissue bank. Regenerative medicine experts with more 15 years of experience in the field will train attendees and provide the necessary tools to implement regulatory and clinical guidelines in a cGMP laboratory setting

The graduate course is to be held four times in Miami in 2015.

Course details, objectives and instruction include:

Didactic Lectures will include:

For additional information, visit the Stem Cell Training, Inc. website, email info(at)stemcelltraining(dot)net, or call 305-224-1858.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

More here:
Global Stem Cell Groups Stem Cell Training to Launch Post-graduate Studies Program in Stem Cell Therapies and ...

Posted in Regenerative Medicine | Comments Off on Global Stem Cell Groups Stem Cell Training to Launch Post-graduate Studies Program in Stem Cell Therapies and …

Stem cell modelling to aid schizophrenia: UOW researchers

Posted: December 2, 2014 at 7:47 am

Dec. 2, 2014, 7:03 p.m.

University of Wollongong researchers are using living human stem cells to build brain tissue that could one day be used to treat neural diseases like schizophrenia and epilepsy.

Stem cell expert Professor Jeremy Crook is working on neural diseases. Picture: GREG TOTMAN

University of Wollongong researchers are using living human stem cells to build brain tissue that could one day be used to treat neural diseases like schizophrenia and epilepsy.

The practice is called disease modelling and is intended to offer a more relevant alternative to animal testing.

Stem cell expert Professor Jeremy Crook believes tissue in development at Innovation Campus' Australian Research Council Centre of Excellence for Electromaterials Science (ACES) is two to three years away from the point where it could be used to test drug compounds.

Researchers also hope to identify cells within the lab-born tissue that could be recruited by the brain and integrated into the site of an injury or disease.

"The other option might be to use these [systems] to optimise biomaterial medical devices that could be implanted and interact on the cells of the brain," Professor Crook said.

"For example, in the case of epilepsy ... normalising cell function to prevent the onset of a seizure and the same with schizophrenia - you might be able to prevent the onset of a schizophrenic episode."

The tissue is made using natural stem cells applied through a 3D printer.

The rest is here:
Stem cell modelling to aid schizophrenia: UOW researchers

Posted in Stem Cells | Comments Off on Stem cell modelling to aid schizophrenia: UOW researchers

Kidney organ regeneration research leaps forward

Posted: December 2, 2014 at 7:41 am

Okayama City, Japan (PRWEB UK) 2 December 2014

Researchers at Okayama University Graduate School of Medicine and Kyorin University School of Medicine have successfully generated a kidney-like structure from just a single cell.

It has been predicted that the kidney will be among the last organs successfully regenerated in vitro due to its complex structure and multiple functions, states Shinji Kitamura, Hiroyuki Sakurai and Hirofumi Makino at the beginning of their latest report, before continuing to describe results suggesting a far more positive prognosis for the pace of kidney regeneration research. Despite the anatomical challenges posed by the kidney anatomy and the complexities understood from embryonic kidney development processes, the researchers have demonstrated that kidney-like structures can be generated from just a single adult kidney stem cell.

In embryos, kidney development requires two types of primordial cells cells at the earliest stage of development. However by generating kidney-like structures from a single type of kidney stem cell the researchers provide evidence for differences in the organ development in adults and embryos.

Kitamura, Sakurai and Makino researchers from Okayama and Kyorin Universities - took kidney stem cells from the different kidney components of microdissected adult rats and grew them in culture. A method for growing three-dimensional cell clusters showed that kidney-like structures could form so long as the initial cell cluster was large enough.

The minimum cluster size required might suggest that not all the kidney stem cells have stem cell characteristics. Therefore the researchers cloned kidney stem cells and confirmed that kidney-like structures still formed from the clusters of clone cells after a few weeks.

The researchers add, Although the physiological roles of such cells are currently unclear, analogous cells in the adult human kidney would be a valuable resource for the regeneration of kidneys in vitro.

Background Kidney structure There are more than a dozen distinct types of cell in the kidneys. The basic structural unit of the kidney is the nephron, which filters the blood to regulate the concentration of water and soluble substances such as sodium salts. Each nephron comprises several well-defined segments: the glomerulus, the proximal tubule, the loop of Henle, the distal tube and the collecting duct.

In embryo kidney organogenesis two primordial cell types are required to differentiate into all the different cell types in the kidney: metanephric mesenchymal cells and uteric bud cells. Kitamura, Sakurai and Makino produced kidney cells that could differentiate into a kidney-like structure without these primordial cell types, suggesting these are adult kidney stem cells.

Obtaining kidney stem cells The researchers microdissected adult rat kidneys into segments from the glomeruli, proximal convoluted tubule (S1/PCT), proximal straight tubule (S2, S3), medullary thick ascending limb of Henles loop and the collecting duct. They then grew the cells on mouse mesenchymal cells. While there is no known single biomarker for adult kidney stem cells, immunohistochemical anaylysis identified a number of markers in the kidney stem cells- that are found in embryonic or adult kidneys.

Go here to see the original:
Kidney organ regeneration research leaps forward

Posted in Cell Medicine | Comments Off on Kidney organ regeneration research leaps forward

James A. Thomson – Wisconsin Stem Cell Research Program

Posted: December 1, 2014 at 2:54 pm

Director of Regenerative Biology, Morgridge Institute for Research / Professor of Cell and Regenerative Biology (UW) / Professor, Molecular, Cellular, and Developmental Biology - University of California, Santa Barbara

In the early 1990s, my lab derived ES cells from an Old World monkey (the rhesus macaque) and a New World monkey (the common marmoset), work that led to derivation of human ES cells in 1998. Much of my labs research after that derivation was dedicated to establishing human ES cells as an accepted, practical model system. To that end, we developed defined culture conditions, methods for genetic manipulation, and approaches for the in vitro differentiation of human ES cells to key lineages of clinical importance including hematopoietic, neural, cardiac, and placental tissues. More recently, in 2007, my laboratory described the isolation of human induced pluripotent (iPS cells) cells with the basic properties of human ES cells but derived from somatic cells.

My research now focuses on understanding how a cell can maintain or change identity, how a cell chooses between self-renewal and the initial decision to differentiate, and how a differentiated cell with limited developmental potential can be reprogrammed to a pluripotent cell.

My current research interests include:

The rest is here:
James A. Thomson - Wisconsin Stem Cell Research Program

Posted in Wisconsin Stem Cells | Comments Off on James A. Thomson – Wisconsin Stem Cell Research Program

Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell …

Posted: December 1, 2014 at 2:44 pm

Background

We previously showed that consolidation therapy with thalidomide and prednisolone improved progression-free and overall survival in patients with multiple myeloma who had undergone autologous stem-cell transplantation. We aimed to assess whether these survival advantages were durable at 5 years.

The ALLG MM6 trial was a multicentre, open-label, randomised phase 3 trial done between Jan 13, 2002, and March 15, 2005, at 29 sites in Australia and New Zealand. Patients with newly diagnosed multiple myeloma were randomly assigned (1:1), via computer-generated randomisation charts, to receive indefinite prednisolone maintenance alone (control group) or in combination with 12 months of thalidomide consolidation (thalidomide group) after autologous stem-cell transplantation. Randomisation was stratified by treating centre and pre-transplantation concentrations of 2 microglobulin. Patients and treating physicians were not masked to treatment allocation. Primary endpoints were progression-free survival and overall survival. Analysis was by intention to treat. Secondary endpoints were overall response to salvage therapy, incidence of second primary malignancy incidence, and cost-effectiveness. This trial is registered with the Australian and New Zealand Clinical Trials Registry, number ACTRN12607000382471.

We randomly assigned 269 patients to the thalidomide (n=114) or control group (n=129). After a median follow-up of 54 years (IQR 3172), estimated 5-year progression-free survival was 27% (95% CI 2332) in the thalidomide group and 15% (1118) in the control group (hazard ratio [HR] 016, 95% CI 0044058; p=00054) and 5-year overall survival was 66% (95% CI 6170) and 47% (4251), respectively (HR 012, 95% CI 0028056; p=00072). There was no difference in overall response to salvage therapy, survival post-progression, or incidence of secondary malignancies between the two groups. Incremental cost-effectiveness ratio was AUS$26996 per mean life-year gained.

Consolidation therapy with thalidomide and prednisolone after autologous stem-cell transplantaion is an acceptable therapeutic approach when alternative drugs are not available.

Pharmion Corporation, Novartis Pharmaceuticals, Amgen Australia, The Merrin Foundation, and Alfred Health.

See the original post:
Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell ...

Posted in Stem Cell Therapy | Comments Off on Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell …

ACell + PRP Stem Cell Hair Regrowth Treatment | Houston Hair Surgeon Dr. Dan McGrath – Video

Posted: December 1, 2014 at 2:46 am


ACell + PRP Stem Cell Hair Regrowth Treatment | Houston Hair Surgeon Dr. Dan McGrath
http://mcgrathmedical.com Dr. Dan McGrath performs ACell Hair Regrowth Injection Therapy with adult stem cells from the patient #39;s own platelet rich plasma or PRP. Broadcast on MY FOX TV - Houston.

By: McGrath Medical

See more here:
ACell + PRP Stem Cell Hair Regrowth Treatment | Houston Hair Surgeon Dr. Dan McGrath - Video

Posted in Stem Cells | Comments Off on ACell + PRP Stem Cell Hair Regrowth Treatment | Houston Hair Surgeon Dr. Dan McGrath – Video

Page 1,919«..1020..1,9181,9191,9201,921..1,9301,940..»